Rattanawong P, Shen W, El Masry H, Sorajja D, Srivathsan K, Valverde A
J Am Heart Assoc. 2020; 9(14):e017529.
PMID: 32515253
PMC: 7660727.
DOI: 10.1161/JAHA.120.017529.
Meraj K, Mahto M, Christina N, Desai N, Shahbazi S, Bhaskar M
Bioinformation. 2013; 8(23):1139-46.
PMID: 23275710
PMC: 3530882.
DOI: 10.6026/97320630081139.
Ezekowitz M, Lampert R
J Thromb Thrombolysis. 1999; 7(1):33-8.
PMID: 10337358
DOI: 10.1023/a:1008823202712.
Crijns H, Gosselink A, Lie K
Cardiovasc Drugs Ther. 1996; 10(2):145-52.
PMID: 8842506
DOI: 10.1007/BF00823592.
Symanski J, GETTES L
Drugs. 1993; 46(2):219-48.
PMID: 7691513
DOI: 10.2165/00003495-199346020-00002.
Effects of the Na+ antagonist cibenzoline on left ventricular function of postischemic hearts.
Hoffmeister H, Beyer M, Seipel L
Cardiovasc Drugs Ther. 1995; 9(2):351-7.
PMID: 7662603
DOI: 10.1007/BF00878681.
[The effect of disopyramide of left ventricular function: an echocardiographic study of the extent and time course (author's transl)].
Angermann C, Autenrieth G
Klin Wochenschr. 1981; 59(14):803-11.
PMID: 7265814
DOI: 10.1007/BF01724687.
Acute cardiac failure and hepatic ischemia induced by disopyramide phosphate.
Scheinman S, Poll D, Wolfson S
Yale J Biol Med. 1980; 53(5):361-6.
PMID: 7222741
PMC: 2595921.
Adverse effects of antiarrhythmic drugs.
Schwartz J, Keefe D, Harrison D
Drugs. 1981; 21(1):23-45.
PMID: 7009136
DOI: 10.2165/00003495-198121010-00002.
New antiarrhythmic drugs: their place in therapy.
Keefe D, Kates R, Harrison D
Drugs. 1981; 22(5):363-400.
PMID: 6800757
DOI: 10.2165/00003495-198122050-00002.
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.
Kumana C, Rambihar V, Willis K, Gupta R, Tanser P, Cairns J
Br J Clin Pharmacol. 1982; 14(4):529-37.
PMID: 6753888
PMC: 1427608.
DOI: 10.1111/j.1365-2125.1982.tb02024.x.
A placebo-controlled study to determine the efficacy of oral disopyramide phosphate for the prophylaxis of ventricular dysrhythmias after acute myocardial infarction.
Kumana C, Rambihar V, Tanser P, Cairns J, Gupta R, Wildeman R
Br J Clin Pharmacol. 1982; 14(4):519-27.
PMID: 6753887
PMC: 1427600.
DOI: 10.1111/j.1365-2125.1982.tb02023.x.
The antiarrhythmic effects of controlled release disopyramide phosphate and long acting propranolol in patients with ventricular arrhythmias.
Fechter P, Ha H, Follath F, Nager F
Eur J Clin Pharmacol. 1983; 25(6):729-34.
PMID: 6662171
DOI: 10.1007/BF00542510.
Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Lima J, Haughey D, Leier C
J Pharmacokinet Biopharm. 1984; 12(3):289-313.
PMID: 6502472
DOI: 10.1007/BF01061722.
Severe hypoglycemia associated with disopyramide.
Nappi J, Dhanani S, Lovejoy J, VanderArk C
West J Med. 1983; 138(1):95-7.
PMID: 6404062
PMC: 1010652.
Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group.
Postgrad Med J. 1984; 60(700):98-107.
PMID: 6369290
PMC: 2417724.
DOI: 10.1136/pgmj.60.700.98.
Amiodarone for refractory cardiac arrhythmias: 10-year study.
LEAK D, Eydt J
CMAJ. 1986; 134(5):495-501.
PMID: 3948063
PMC: 1490798.
Haemodynamic effects of class I antiarrhythmic agents.
Legrand V, Collignon P
Drugs. 1985; 29 Suppl 4:54-7.
PMID: 3924551
DOI: 10.2165/00003495-198500294-00011.
Pharmacokinetics and haemodynamic effects of tocainide in patients with acute myocardial infarction complicated by left ventricular failure.
MacMahon B, Bakshi M, Branagan P, Kelly J, Walsh M
Br J Clin Pharmacol. 1985; 19(4):429-34.
PMID: 3922392
PMC: 1463818.
DOI: 10.1111/j.1365-2125.1985.tb02666.x.
Evaluation of the negative inotropic effect.
Sami M
Eur J Clin Pharmacol. 1987; 31(6):739.
PMID: 3556383
DOI: 10.1007/BF00541308.
